Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Papp, Kim; Lebwohl, Mark; Puig, L.; Ohtsuki, Mamitaro; Beissert, Stefan; Zeng, J.; Rubant, Simone; Sinvhal, Ranjeeta; Zhao, Yiwei; M. Soliman, Ahmed; Alperovich, Gabriela; Leonardi, C.

doi:10.1111/bjd.20595

Public

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Published in British Journal of Dermatology • Jun 22, 2021

Authors:

Kim Papp

Mark Lebwohl

L. Puig

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long-term evaluation to assess the durability of their efficacy and safety profiles over time. OBJECTIVES: To evaluate the long-term efficacy and safety of risankizumab (RZB) fo...

Subject

Psoriasis Area and Severity Index

Medicine

Dermatology Life Quality Index

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!